Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
Viruses · 07.03.2023 · 15 (3) · 698
DOI: 10.3390/v15030698 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 07.03.2023. Verfasst von Kenneth Lundstrom. Beteiligte Einrichtung: PanTherapeutics, CH1095 Lutry, Switzerland. Hauptthemen laut MEDLINE: Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 191-mal zitiert (Crossref) und nennt 282 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Viral vectors have been used for a broad spectrum of gene therapy for both acute and chronic diseases. In the context of cancer gene therapy, viral vectors expressing anti-tumor, toxic, suicide and immunostimulatory genes, such as cytokines and chemokines, have been applied. Oncolytic viruses, which specifically replicate in and kill tumor cells, have provided tumor eradication, and even cure of cancers in animal models. In a broader meaning, vaccine development against infectious diseases and various cancers has been considered as a type of gene therapy. Especially in the case of COVID-19 vaccines, adenovirus-based vaccines such as ChAdOx1 nCoV-19 and Ad26.COV2.S have demonstrated excellent safety and vaccine efficacy in clinical trials, leading to Emergency Use Authorization in many countries. Viral vectors have shown great promise in the treatment of chronic diseases such as severe combined immunodeficiency (SCID), muscular dystrophy, hemophilia, β-thalassemia, and sickle cell disease (SCD). Proof-of-concept has been established in preclinical studies in various animal models. Clinical gene therapy trials have confirmed good safety, tolerability, and therapeutic efficacy. Viral-based drugs have been approved for cancer, hematological, metabolic, neurological, and ophthalmological diseases as well as for vaccines. For example, the adenovirus-based drug Gendicine® for non-small-cell lung cancer, the reovirus-based drug Reolysin® for ovarian cancer, the oncolytic HSV T-VEC for melanoma, lentivirus-based treatment of ADA-SCID disease, and the rhabdovirus-based vaccine Ervebo against Ebola virus disease have been approved for human use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PanTherapeutics, CH1095 Lutry, Switzerland.
Zitieren
APA
Lundstrom, K. (2023). Viral Vectors in Gene Therapy: Where Do We Stand in 2023?. Viruses, 15(3), 698. https://doi.org/10.3390/v15030698
Vancouver
Lundstrom K. Viral Vectors in Gene Therapy: Where Do We Stand in 2023?. Viruses. 2023;15(3):698. doi:10.3390/v15030698
BibTeX
@article{Lundstrom2023,
author = {Lundstrom, Kenneth},
title = {Viral Vectors in Gene Therapy: Where Do We Stand in 2023?},
journal = {Viruses},
year = {2023},
volume = {15},
number = {3},
pages = {698},
doi = {10.3390/v15030698}
}
EUVIMED